|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||152.02 - 154.55|
|52 Week Range||116.50 - 160.62|
|PE Ratio (TTM)||32.97|
|Earnings Date||Jan 22, 2018 - Jan 26, 2018|
|Forward Dividend & Yield||1.88 (1.23%)|
|1y Target Est||160.30|
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Stryker Corp. a score of 72. Our analysis is based on comparing Stryker Corp. with the following peers – Zimmer Biomet Holdings, Inc., Smith & Nephew PLC Sponsored ADR, Medtronic plc, Edwards Lifesciences Corporation, Boston Scientific Corporation, Baxter International Inc., Integra LifeSciences Holdings Corporation, Exactech, Inc., Hill-Rom ... Read more (Read more...)
Kalamazoo, Michigan - December 12, 2017 - Stryker Corporation (NYSE:SYK) announced today that after 44 years of distinguished service, Mr. Howard E. Cox, Jr. has notified the Company that he will not stand ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Stryker Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
NEW ORLEANS , Dec. 11, 2017 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
Kalamazoo, Michigan - December 11, 2017 - Stryker Corporation (NYSE:SYK) announced that the simplified public tender offer for the shares and BSAAR warrants of VEXIM, a French medical device company listed ...
Medical-device maker Entellus Medical Inc. has reached a deal to be sold to Stryker Corp. in a deal worth roughly $662 million, the companies announced Thursday. Kalamazoo, Mich.-based med-tech giant Stryker (SYK) will buy Entellus for $24 per share. Stryker, which generated $11.3 billion in sales last year, will incorporate Entellus (ENTL) into its unit that sells for devices for treating ear, nose and throat conditions.
Medical device maker Stryker Corp said on Thursday it would buy Entellus Medical Inc for $662 million, adding heft to its ear, nose and throat business. Stryker would pay $24 per Entellus share, a premium ...
Medical device maker Stryker Corp said on Thursday it would buy medical technology company Entellus Medical Inc in a deal valued at about $662 million, adding heft to its ENT business. Stryker would pay $24 per Entellus share, a premium of about 50 percent to Entellus's Wednesday close. The deal to expected to be dilutive to Stryker's 2018 adjusted net earnings per share by about 4 cents, but accretive thereafter, the company said.
Entellus Medical Inc. said Thursday it has reached a deal to be acquired by Stryker Corp. for $24 a share in cash, in a deal with an equity value of about $662 million. Entellus is a leader in technology ...
Kalamazoo, Michigan - December 7, 2017 - Stryker Corporation (NYSE: SYK) announced today a definitive merger agreement to acquire Entellus Medical, Inc. (NASDAQ: ENTL) for $24.00 per share, or an equity ...
PLYMOUTH, Minn., Dec. 07, 2017-- Entellus Medical, Inc. announced today a definitive merger agreement by which Stryker Corporation will acquire Entellus in an all cash transaction for $24.00 per share, ...
Kalamazoo, Michigan - December 6, 2017 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.
On November 9, 2017, Stryker (SYK) announced FDA approval for the Neuroform Atlas Stent System, which is approved for marketing under an HDE.
On November 28, 2017, Howmedica Osteonics, an orthopedics subsidiary of Stryker (SYK) and Zimmer Biomet Holdings (ZBH), settled a trade secret case.
As of November 30, 2017, in a Reuters survey of 27 investment research companies, ~63% or 17 firms recommended Stryker stock as a "buy."
Stryker Corporation (NYSE:SYK) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. As a large-cap stock with high coverage by analysts,Read More...
Stryker (SYK) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Stryker Corp. Here are 5 ETFs with the largest exposure to SYK-US. Comparing the performance and risk of Stryker Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)